All AbMole products are for research use only, cannot be used for human consumption.
SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, >100-fold selectivity over TGF-βRII. SD-208 blocka TGF-beta-induced phosphorylation of the receptor-associated Smads, Smad2 and Smad3, and stimulates epithelial-to-mesenchymal transdifferentiation, migration, and invasiveness into Matrigel in vitro.In the murine aortic allograft model, SD-208 effectively reduces the formation of intimal hyperplasia of transplant arteriosclerosis (TA).
 |
Source | J Neurosci (2016). Figure 5. SD-208 |
| Method | i.p. | |
| Cell Lines | EAN rats | |
| Concentrations | 20 mg/kg/d | |
| Incubation Time | 12 day | |
| Results | In both the SD-208 alone and RvD1 + SD-208 groups, EAN rats showed much more severe neurological scores and significantly prolonged disease duration, not only compared with the RvD1 + vehicle group, but also compared with the vehicle-alone group (Fig. 5B), suggesting that the inhibition of TGF-β signaling not only abolished the exogenous RvD1 effects, but also may suppress endogenous RvD1 functions. |
| Cell Experiment | |
|---|---|
| Cell lines | Murine SMA-560 or human LN-308 glioma cells |
| Preparation method | Proliferation. Glioma cells were cultured in the absence or presence of SD-208 (1 μmol/L) for 48 hours. The cells were pulsed for the last 24 hours with [methyl-3H]thymidine (0.5 μCi) and harvested (Tomtec, Hamden, CT), and incorporated radioactivity was determined in a liquid scintillation counter (Wallac, Turku, Finland). |
| Concentrations | 1 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | SMA-560 cells bearing VM/Dk mice |
| Formulation | deionized water |
| Dosages | 1 mg/mL |
| Administration | p.o. |
| Molecular Weight | 352.75 |
| Formula | C17H10ClFN6 |
| CAS Number | 627536-09-8 |
| Solubility (25°C) | DMSO 8 mg/mL warmed |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related TGF-β Receptor Products |
|---|
| LY2157299
LY2157299 (Galunisertib) is a novel clinically relevant TBRI (ALK5 kinase) inhibitor with IC50 of 56 nM. |
| GW788388
GW788388 is a potent selective inhibitor of TGF-beta type I receptor and ALK5 with IC50 values of 0.093 and 0.018 μM. |
| LY364947
LY364947 is a selective small molecule inhibitor of the TGFβ type I receptor kinase with IC50 of 59 nM. |
| LY2109761
LY2109761 is a novel TGF-β receptor type I and type II dual inhibitor, with Ki values of 38 nM and 300 nM, respectively. |
| SB-525334
SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
